NOTE: By submitting this form and registering with us, you are providing us with permission to store your personal data and the record of your registration. In addition, registration with the Medical Independent includes granting consent for the delivery of that additional professional content and targeted ads, and the cookies required to deliver same. View our Privacy Policy and Cookie Notice for further details.
Don't have an account? Subscribe
Priscilla Lynch provides a round-up of some of the most topical research presented at this year’s EULAR Congress, which took place virtually from 2-5 June
Sacroiliitis is linked to the disease axial spondyloarthritis (axSpA) and visible on X-ray. Observational cohort studies have shown that there is low, but still detectable progression in radiographic sacroiliitis, which might also have an impact on the function in patients with axSpA. Recent data show that tumour necrosis factor inhibitors (TNFi) might slow spinal progression when started earlier and taken for longer. However, the question of whether they also have such an effect on radiographic progression in sacroiliac joints is still unclear.
Murat Torgutalp and colleagues investigated the longitudinal association between radiographic sacroiliitis progression and treatment with TNFi in patients with early axSpA in a long-term inception cohort. The results were shared in an oral session at the 2021 EULAR Congress. Based on the availability of at least two sets of sacroiliac joint (SIJ) radiographs, 166 patients with non-radiographic axial spondyloarthritis (nr-axSpA), and 135 with radiographic (r-axSpA), from the German Spondyloarthritis Inception Cohort (GESPIC) were included in the analysis.
Observational cohort studies have shown that there is low, but still detectable progression in radiographic sacroiliitis
Two trained and calibrated central readers scored the radiographs, and if both scored an image as definite radiographic sacroiliitis, the patient was classified as having r-axSpA. The association between previous and current TNFi use, and change in the sacroiliitis sum score over two years was analysed.
At baseline, nine (3.0 per cent) patients were treated with a TNFi, and 87 (28.9 per cent) patients received at least one TNFi during the entire follow-up period. While receiving 12 or more months of TNFi in the previous interval was associated with lower progression of the sacroiliitis sum score compared to not receiving TNFi in the previous interval, this was not the case in patients who received TNFi for longer than 12 months in the current two-year interval.
The significant association between TNFi use for longer than 12 months in the previous interval and progression in the sacroiliitis sum score were confirmed in the adjusted analysis. In addition, a similar trend for the beneficial effects was observed in different models, which included other treatment definitions with TNFi in the previous two-year interval.
The authors concluded that TNFi treatment was associated with slowing radiographic sacroiliitis progression in people with axSpA. This effect became evident two-to-four years after treatment initiation.
The final presentation at the Irish Society for Rheumatology Spring Meeting 2023 was delivered by Dr...
Attendees at the Irish Society for Rheumatology Spring Meeting 2023 heard from Dr Brenda Griffin, Consultant...
The Judge's report proposes that a Tribunal be established under legislation to hear and determine claims...
In December, the HSE released part of an external review into the case of 'Brandon', a...
The evidence on doctor burnout “should scare us and concern us”, the Director of the RCSI...
A review of public health governance structures and addressing “longstanding” IT infrastructure...
Leave a Reply
You must be logged in to post a comment.